Digoxin: Nursing Drug Guide, Toxicity & Apical Pulse
Narrow therapeutic index: count the apical pulse for a full minute, correct potassium and magnesium before dosing when possible, and treat new GI or visual symptoms as possible toxicity—not routine aging.
Toxic digoxin levels are only slightly above therapeutic levels. Hypokalemia, hypomagnesemia, hypercalcemia, renal impairment, and interacting drugs increase toxicity risk. Early cues include anorexia, nausea, vomiting, visual changes, and new cardiac arrhythmias—including bradycardia and heart block. Life-threatening toxicity may require Digoxin Immune Fab per prescribing information.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: apical pulse × 1 minute, potassium trend, renal function, and toxicity screen (GI, vision, rhythm). Hold and clarify when pulse is slow, electrolytes are unsafe, or toxicity is suspected—then monitor response after any dose change or level draw.
Most common brand names
Digoxin tablets are available generically from multiple manufacturers (for example Hikma Pharmaceuticals USA) and historically under the Lanoxin brand. Imprint and color differ between strengths: always match the MAR to the packaged tablet appearance (deboss pattern and formulation) rather than guessing from legacy mnemonics.
Patients on guideline-directed therapy for heart failure or rate control during atrial fibrillation often carry overlapping prescriptions; formal handoff reconciliation should remain part of nurse-driven admission and discharge QA even when pharmacy leads the MAR build.
Why we give it — Indications
Hikma prescribing information defines digoxin tablets as a cardiac glycoside indicated for mild to moderate heart failure in adults (often alongside diuretics and ACE inhibitors per label wording), increasing myocardial contractility in pediatric patients with heart failure, and controlling resting ventricular response in adults with chronic atrial fibrillation. Nurses should relate each indication to symptom burden (shortness of breath, subtle exercise intolerance, resting palpitations) and monitored rhythm endpoints.
| Use | Detail |
|---|---|
| Adult HF (mild–moderate) | Increases left ventricular ejection fraction and HF symptoms while not affecting mortality. |
| Pediatric HF | Increases myocardial contractility in pediatric HF; tablet dosing feasibility depends on pediatric formulation availability per protocol. |
| Chronic AF (adults) | Control of resting ventricular response rate alongside vigilance for heart arrhythmia-related perfusion collapse when rate-control goals slip. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Per the prescribing information for digoxin tablets, pharmacologic actions are mediated through inhibition of membrane Na‑K ATPase. Consequences stated in labeling include enhanced myocardial inotropy, nodal slowing (negative chronotropic and AV nodal slowing effects via parasympathetic tone), modulation of sympathetic and renin-angiotensin signaling at therapeutic dosing, progressive potassium effects at rising concentrations, and characteristic electrocardiogram (ECG) changes (for example PR prolongation during therapeutic use—not automatically diagnostic of toxicity). These mechanisms bridge contractility symptoms in systolic dysfunction and controlled ventricular response in fibrillation pathways.
Dosing overview
Label dosing is individualized by age, lean body weight, renal function, and interacting drugs—toxic levels are only modestly higher than therapeutic levels.
Drug level timing: Obtain serum concentrations just before the next scheduled dose or at least six hours after the last dose.
Pediatric patients younger than ten years receive different oral maintenance dosing in the prescribing information—follow specialist tables rather than extrapolating from adult summaries.
Before you give it — Safety check
Pretreatment checks
- Measure apical pulse (full minute) before administration; withhold and clarify rhythm or rate abnormalities per prescriber and protocol thresholds
- Review electrolytes (basic metabolic panel, potassium), renal trend (serum creatinine, estimated glomerular filtration rate from the same renal panel) because hypokalemia, hypomagnesemia, hypercalcemia, and renal impairment predispose to toxicity
- Identify interacting agents; with amiodarone the label guides measuring digoxin first and lowering digoxin dose by roughly 30–50% while monitoring
Contraindications
- Ventricular fibrillation
- Known hypersensitivity to digoxin or other digitalis preparations (hypersensitivity may include airway or mucosal involvement per label wording)
Patients who develop AF with accessory AV pathways (for example Wolff-Parkinson-White phenotype) carry risk of accelerated ventricular response leading toward ventricular fibrillation if digoxin preferentially slows the AV node; align therapy with specialty guidance.
Administration
Route: Oral scored tablets.
- Use two-nurse verification or barcode scanning per policy for narrow-index microgram dosing and look-alike strength risk
- Assess apical pulse rate and rhythm for a full minute immediately before dosing; hold and notify when outside ordered parameters rather than extrapolating a radial check alone when policy requires central assessment
- Administer consistently relative to labs and trough drug levels drawn per protocol; reinforce fall precautions when dizziness overlaps expected HF symptoms
Hold or reduce digoxin shortly before elective cardioversion per prescriber plan to lower ventricular arrhythmia risk; use minimal energy when urgent cardioversion cannot wait.
Expected therapeutic response
- For HF indication: gradual improvement or stabilization in exercise tolerance and congestion burden when combined with guideline-directed therapies
- For chronic AF indication: clinically acceptable resting ventricular rate trajectory without symptomatic hypotension attributable solely to inappropriate rate control dosing
- Serum concentrations maintained in a clinician-defined window—not isolated numbers without symptoms
Red flags — Stop and act
Escalate when perfusion declines, ingestion errors microgram-milligram, or toxicity arrhythmias appear.
- New gastrointestinal intolerance (nausea), anorexia, or visual disturbances suggestive of digoxin toxicity
- New high-grade AV block, rapid irregular wide-complex tachycardia, or multimorphic ventricular ectopy clusters
- Symptomatic bradycardia or syncope with changing pulse character after dose escalation
- Acute deterioration after macro-dose ingestion (protocol-driven toxicology escalation)
- Escalating confusion or sudden fatigue out of proportion to sleep, perfusion alarms, or dizziness in the setting of electrolyte disturbances or rising creatinine
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Cardiac toxicity | Accounts for roughly half of serious digoxin-associated events overall | Continuous telemetry per protocol; obtain ECG fragments; escalate arrhythmias that match toxicity patterns |
| GI disturbance | Approximates one-quarter of serious events; overlaps HF symptoms | Differentiate escalation of HF versus toxicity via labs, serum digoxin interpretation, rhythm strip |
| Visual changes | Chromatopsia emphasized in overdose narratives | Teach symptom reporting promptly; withhold further doses pending review when coupled with cardiac signs |
| CNS effects | Includes confusion, dizziness, hallucinations at higher exposures | Safety rounds; medication review; escalate if cognition shifts without alternative cause |
| General trial context | Hospitalization for suspected toxicity ~2% in DIG trial placebo-controlled cohort | Stress serum monitoring when symptoms blur with underlying HF trajectory |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and supportive care
Chronic overdose management starts with withholding digoxin and placing the patient on monitored care, correcting reversible contributors and targeting serum potassium roughly 4.0–5.5 mmol/L when hypokalemia drives arrhythmia risk while avoiding potassium in advanced bradyarrhythmia or block without clinician direction. Potassium administration requires ECG vigilance.
Massive ingestion
- Activated charcoal (oral or NG) regardless of ingestion interval because enteric cycling recycles drug
- Life-threatening rhythm disturbances or hyperkalemia may warrant Digoxin Immune Fab administration; dialysis does not materially clear digoxin
For ventricular tachycardia, ventricular fibrillation, advanced AV block refractory to atropine, or hyperkalemia with hemodynamic instability, activate emergency protocols and institute Digoxin Immune Fab per formulary dosing tables—document timing, vitals rhythm strips, electrolytes.
Suspected adverse reactions should be escalated through your facility’s pharmacovigilance pathway and documented per local policy; further granularity is not outlined in bedside workflow standards beyond prompting formal institutional reporting.
Look-alike / sound-alike and error prevention
- Digoxin vs digitoxin — distinct cardiac glycosides with different dosing and kinetic profiles despite similar names
- 125 mcg versus 250 mcg tablets — double-check microgram arithmetic; barcode scan both package and blister
- Lanoxin brand confusion — verify whether the regimen references historic brand stocking versus generic digoxin equivalents on the MAR
- Independent double-check protocols — align second nurse verification thresholds with organization’s high-risk oral medication policies even when broader ISMP classifications differ
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Apical pulse ritual | Perform before every dose whenever policy demands; document irregularity—even without symptoms—before titrating as-needed adjunct rate-control measures. |
| Renal dosing discipline | Maintenance tables scale to creatinine clearance; repeat basic metabolic surveillance after dehydration or diuresis swings. |
| Electrolyte interplay | Hypokalemia magnifies ectopy despite “normal therapeutic” serum digoxin readings—pair with clinician potassium repletion pathways. |
| Acute coronary context | Label cautions digoxin during acute heart attack because of heightened myocardial oxygen demand—not a substitute pathway for acute coronary syndrome management. |
| HF mimic | When toxicity and worsening HF share exertional intolerance or subjective breathlessness cues, escalate for serum assay before independently uptitrating inotrope therapy. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Renal impairment | Drug cleared renally—expect prolonged half-life and higher steady-state exposures if dose is uncorrected. |
| Older adults | Age-associated renal decline lowers clearance; maintain lean-body-weight dosing awareness when edema or obesity distort total weight cues. |
| Electrolyte volatility | Vomiting, aggressive diuresis, or dialysis shifts quickly change vulnerability even when digoxin doses remain constant. |
| Pregnancy | Human data compiled in labeling have not defined a distinctive major malformation signal; untreated maternal HF or AF still threatens mother and fetus. Digoxin crosses placenta—monitor neonates for vomiting and cardiac arrhythmias. Requirements often rise during pregnancy and fall postpartum—serum surveillance per prescriber. |
| Lactation | Manufacturer risk summary estimates infant intake up to roughly 4% of neonatal maintenance dose with limited clinical relevance. LactMed (NBK501845) summarizes low milk levels generally compatible with breastfeeding for oral maternal therapy; maternal IV dosing guidance there suggests considering a brief pump-and-discard window after infusion if minimizing infant exposure matters clinically. |
On a small screen, swipe or scroll sideways to see the full table.
Newborn neonatal tolerance is variable; premature neonates exhibit heightened sensitivity—pediatric dosing must be individualized per specialty protocol.
Monitoring and documentation
Monitor
- Apical rate and rhythm, blood pressure, perfusion cues linked to vital signs monitoring bundles
- Magnesium, ionized calcium when protocol dictates, and enteral chloride-based potassium supplementation—milliequivalent teaching stays separate from microgram digoxin arithmetic
- Estimated glomerular filtration rate trending whenever serum creatinine climbs or adjunct diuresis introduces volume shifts
- Drug levels correlated with dosing times; note assay interference considerations listed in prescribing information where applicable
Document
- Pulse measurement site, technique (full-minute apical), and withhold/notify actions taken
- Tablet strength administered in micrograms, patient education delivered, barcode scan confirmation
- Escalations for ectopy clusters, ingestion errors, electrolyte-mediated risk, or dialysis-related kinetic shifts
Patient teaching
- Use teach-back explaining microgram dosing—patients confuse mcg versus mg routinely
- Review visual changes together with gastrointestinal upset (for example nausea, vomiting, color tinges) prompting urgent clinician contact—not elective next-day clinics when progression is brisk
- Discuss stable timing for labs tied to dosing so serum digoxin interpretations stay interpretable per laboratory guidance
- Reinforce that missed doses generally should not be doubled unless prescriber instructs explicitly
- Counsel breastfeeding parents to defer to lactation clinician if maternal route switches to IV dosing or hospitalization complicates pumping plans
The Hold Rule
Do not administer and escalate per protocol when acute safety triggers appear:
- Pulse outside prescriber parameters or clinically unstable bradyarrhythmia after recent dose adjustments
- Acute ingestion far exceeding MAR with evolving arrhythmias or hyperkalemia
- New high-grade AV block or symptomatic ectopy clustering until cardiology-directed plan exists
- Serum potassium or magnesium extremes without correction strategy
- Worsening renal failure with escalating digoxin exposure risk absent immediate level review when symptoms appear
Hold wording beyond these emergency triggers—including narrow rate windows for chronic AF—should mirror written orders rather than improvised thresholds.
Clinical practice integration and workflow
Digoxin stewardship nurses pair microgram dosing discipline with longitudinal renal and electrolyte surveillance because therapeutic and toxic exposures live on adjacent concentration bands.
1. Check-before-you-give protocol
- Barcode strength (125 versus 250 mcg) versus MAR microgram order
- Apical rhythm documentation for at least sixty seconds consistent with telemetry when available
- Recent BMP and magnesium status when diarrhea, vomiting, or diuretic changes occurred
- Interaction screen whenever amiodarone loading or antibiotic-mediated P-glycoprotein shifts alter renal clearance unexpectedly
2. High-alert and safety badge
ISMP high-alert: NoDigoxin is not categorized on the publicly circulated ISMP high-alert medication lists but retains an ultra-narrow therapeutic margin—bedside redundancy (double verification, rhythm verification, lab cadence) should remain aggressive.
3. Clinical workflow: hold and question rules
- Hold when toxicity overlaps HF decompensation until serum digoxin and electrolytes adjudicate causality
- Question orders that escalate maintenance doses while levels exceed 2 ng/mL without toxicity documentation rationale
- Coordinate cardioversion-plan hold windows with procedural nursing and sedation teams simultaneously
4. Critical teach-back questions
- “What tablet strength are you supposed to swallow?” The learner states exact micrograms, color awareness if applicable to their dispensing system, never “half a tablet” vagueness unless matches scored instructions.
- “Which sensations mean call today rather than next clinic?” The learner lists persistent vomiting, hallucinations/visual changes with racing pulse sensations, or unexplained faintness.
5. Care coordination
Pharmacist: Dose adjustments when amiodarone or P-glycoprotein modulators initiate, assays skewed by digoxin-like immunoreactive substances, or renal dosing tables require smoothing.
Cardiology / Electrophysiology: Rhythm strategy when AF merges with suspected accessory pathways, refractory tachyarrhythmias, or device-dependent bradycardia.
6. Procedures supporting safe use
Pair digoxin stewardship with meticulous medication reconciliation alongside every medication administration pass—especially whenever diuretics, renin-angiotensin inhibitors, mineralocorticoid antagonists, or other rate-control adjuncts reshuffle concurrently.
🧠 Quick mental checklist
- Did I count the apical pulse for a full minute before this dose?
- What are today’s potassium, magnesium, and renal function trends?
- Any new nausea, anorexia, visual changes, or rhythm symptoms since the last dose?
- Is the patient on amiodarone, verapamil, or loop diuretics that change digoxin levels or toxicity risk?
- If toxicity is suspected, is Digoxin Immune Fab availability confirmed per protocol?
Digoxin NCLEX practice questions
Practice NCLEX-style clinical judgment practice for digoxin using a tabbed inpatient case (MAR, labs, vitals, nursing notes), then priority action, select-all-that-apply cue recognition, electrolyte trend interpretation, matrix urgency sorting, and antidote cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Digoxin 125 mcg PO daily scheduled — due 0900; last given yesterday 0900
- Furosemide 40 mg PO daily — given 0800; urine output increased since dose
- Amiodarone 200 mg PO daily — ongoing home dose continued on admission
- Potassium chloride 20 mEq PO twice daily — patient refused morning dose
- 0905: nurse preparing digoxin after reviewing tabs
- Admission: potassium 4.1 mEq/L; magnesium 1.8 mg/dL; creatinine 1.0 mg/dL; digoxin level pending
- Today 0730: potassium 3.2 mEq/L (↓ from 3.8 two days ago); magnesium 1.6 mg/dL; BUN 28 mg/dL; creatinine 1.3 mg/dL
- Digoxin level (trough) from yesterday: 1.4 ng/mL
- 0800: apical pulse 58/min, irregular; BP 108/62 mmHg; SpO2 94% on room air
- Patient reports “yellow-green halos” around lights since last night
- Telemetry: frequent PVCs; one 6-beat run of wide-complex tachycardia overnight (self-limited)
- 0730: Poor appetite; one episode of non-bloody vomiting; denies abdominal pain
- 0815: Patient confused about date; family reports increased fatigue
- 0845: Pharmacy message — hold digoxin if potassium remains below 3.5 mEq/L until rechecked after supplementation per prescriber
Answer key & rationale
Frequently asked questions
Why must nurses use the apical pulse for digoxin?
Prescribing information instructs patients to monitor and record heart rate and blood pressure daily. At the bedside, a full-minute apical pulse best captures slow or irregular rhythms that radial pulses can miss—especially with atrial fibrillation or frequent ectopy.
When should digoxin be held?
Hold when toxicity is suspected (GI symptoms, visual changes, new arrhythmias), for symptomatic bradycardia or high-grade AV block, for uncorrected hypokalemia per prescriber/pharmacy direction, and for ventricular fibrillation (contraindicated). Follow institution pulse and electrolyte parameters.
What potassium level increases digoxin toxicity risk?
Labeling states hypokalemia predisposes to digoxin toxicity because potassium and digoxin compete for the same binding site on Na-K ATPase. Correct potassium toward the 4.0–5.5 mmol/L range when arrhythmias are present per overdose guidance, and prevent hypokalemia before routine dosing when possible.
What is the antidote for severe digoxin toxicity?
Digoxin Immune Fab (DIGIBIND, DIGIFAB) is indicated for life-threatening toxicity or massive ingestion with serious arrhythmias or hyperkalemia. Supportive care includes cardiac monitoring, electrolyte correction, and activated charcoal when appropriate. Digoxin is not effectively removed by dialysis.
How does amiodarone affect digoxin?
Digoxin tablet labeling reports amiodarone can increase digoxin concentrations and recommends measuring serum digoxin before initiating amiodarone and reducing the digoxin dose by approximately 30 to 50% with continued monitoring.
Is digoxin safe during breastfeeding?
LactMed reports low digoxin levels in breast milk with amounts ingested by the infant estimated at about 1 to 7% of the maternal weight-adjusted dose; studied infants showed no detectable adverse effects. After IV digoxin, avoiding breastfeeding for 2 hours lessens infant exposure.
References
-
U.S. National Library of Medicine. DIGOXIN tablets — Full prescribing information. DailyMed (Hikma Pharmaceuticals USA Inc.; revised June 2024).https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41c16cff-b03e-405e-a617-d6f45d3ce2bd
-
Drugs and Lactation Database (LactMed). Digoxin. Bethesda (MD): National Institute of Child Health and Human Development; updated September 15, 2024.https://www.ncbi.nlm.nih.gov/books/NBK501845/
-
National Institute for Health and Care Excellence. British National Formulary: Digoxin.https://bnf.nice.org.uk/drugs/digoxin/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.